Rani Therapeutics Holdings Stock Today
| RANI Stock | USD 1.31 0.01 0.76% |
Performance0 of 100
| Odds Of DistressOver 84
|
Rani Therapeutics is trading at 1.31 as of the 18th of January 2025. This is a 0.76 percent decrease since the beginning of the trading day. The stock's open price was 1.32. Rani Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of July 2021 | Category Healthcare | Classification Health Care |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company was incorporated in 2012 and is headquartered in San Jose, California. Rani Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 33.31 M outstanding shares of which 1.49 M shares are at this time shorted by private and institutional investors with about 0.36 trading days to cover. More on Rani Therapeutics Holdings
Moving together with Rani Stock
Moving against Rani Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rani Stock Highlights
| Executive Chairman | Mir Imran | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Tel Aviv 60, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRani Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rani Therapeutics' financial leverage. It provides some insight into what part of Rani Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rani Therapeutics Holdings (RANI) is traded on NASDAQ Exchange in USA. It is located in 2051 Ringwood Avenue, San Jose, CA, United States, 95131 and employs 140 people. Rani Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 77.29 M. Rani Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 33.31 M outstanding shares of which 1.49 M shares are at this time shorted by private and institutional investors with about 0.36 trading days to cover.
Rani Therapeutics Holdings currently holds about 98.17 M in cash with (51.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Rani Therapeutics Probability Of Bankruptcy
Ownership AllocationRani Therapeutics owns a total of 33.31 Million outstanding shares. Rani Therapeutics has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Rani Ownership Details
Rani Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Lasry Marc | 2024-09-30 | 62.9 K | |
| Motco | 2024-09-30 | 48.1 K | |
| State Street Corp | 2024-09-30 | 42 K | |
| Renaissance Technologies Corp | 2024-09-30 | 33.2 K | |
| Brown Advisory Holdings Inc | 2024-09-30 | 32.9 K | |
| Citadel Advisors Llc | 2024-09-30 | 26.9 K | |
| Lafayette Investments, Inc. | 2024-09-30 | 19.9 K | |
| Ubs Group Ag | 2024-09-30 | 15.7 K | |
| Prime Capital Investment Advisors, Llc | 2024-09-30 | 11.5 K | |
| Armistice Capital, Llc | 2024-09-30 | 2.6 M | |
| Vanguard Group Inc | 2024-09-30 | 709.8 K |
Rani Therapeutics Historical Income Statement
Rani Stock Against Markets
Rani Therapeutics Corporate Management
| Alireza Javadi | Vice Operations | Profile | |
| Svai Sanford | Chief Officer | Profile | |
| Mir Hashim | Chief Officer | Profile | |
| Arvinder Dhalla | Vice Development | Profile | |
| Bella Vazquez | Vice Resources | Profile | |
| Eric Groen | General Counsel | Profile | |
| Kate MBA | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rani Therapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.